DadFinStart your free week
DadFin › Stocks › Healthcare › ADCT

ADC Therapeutics SA (ADCT) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · Switzerland

$1.73 ▲ +8.81% today

73.6
Dad Score, out of 100
good

ADC Therapeutics SA (ADCT) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in Switzerland. On DadFin's weekly run it scores 73.6 out of 100 on the Dad Score, a good reading that places the business ahead of 74% of the 5,773 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #229 of 968. Its strongest axes are quality, growth and price action; its weakest is valuation.

Scores from the run of Oct 11, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Above average
Growth
Above average
Price action
Strong
Risk
Average
Conviction
Above average
Liquidity
Average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)-1.2×
Dividend yield0.00%
Return on capital-35.6%
Operating margin-118.1%
Revenue growth (YoY)+14.9%
FCF yield-188.6%
Net debt / EBITDA3.00×
Piotroski F-Score6 / 9
52-week change-62.5%
Market cap$221M
Next earningsNov 10, 2026

What subscribers see on ADCT

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi50.0middling$59.8B
TEVATeva Pharmaceutical Industries Lim96.8strong$47.9B
HLNHaleon plc69.5middling$41.0B
ZTSZoetis Inc.94.4strong$30.9B
UTHRUnited Therapeutics Corporation99.1strong$23.6B
VTRSViatris Inc.84.5good$20.3B
NBIXNeurocrine Biosciences, Inc.98.7strong$14.5B
ELANElanco Animal Health Incorporated96.2strong$11.5B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 11, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.